RU2012114261A - ANALGETIC PRODUCT BASED ON PLASMID DNA - Google Patents

ANALGETIC PRODUCT BASED ON PLASMID DNA Download PDF

Info

Publication number
RU2012114261A
RU2012114261A RU2012114261/10A RU2012114261A RU2012114261A RU 2012114261 A RU2012114261 A RU 2012114261A RU 2012114261/10 A RU2012114261/10 A RU 2012114261/10A RU 2012114261 A RU2012114261 A RU 2012114261A RU 2012114261 A RU2012114261 A RU 2012114261A
Authority
RU
Russia
Prior art keywords
plasmid dna
defensin
analgesic
analgetic
gene
Prior art date
Application number
RU2012114261/10A
Other languages
Russian (ru)
Inventor
Илья Владимирович Духовлинов
Борис Владимирович Крылов
Original Assignee
Илья Владимирович Духовлинов
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Илья Владимирович Духовлинов filed Critical Илья Владимирович Духовлинов
Priority to RU2012114261/10A priority Critical patent/RU2012114261A/en
Publication of RU2012114261A publication Critical patent/RU2012114261A/en

Links

Landscapes

  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

1. Анальгетическое средство на основе плазмидной ДНК, с которой в клетках млекопитающих экспрессируется ген дефенсина NP-1, либо модифицированный для увеличения собственной экспрессии ген дефенсина NP-1.2. Анальгетическое средство по п.1 для введения в организм человека и млекопитающих с целью снятия болевого синдрома любой этиологии.3. Анальгетическое средство по п.1, характеризующееся тем, что получено с использованием методов молекулярной биологии, микробиологии и рекомбинантных ДНК, т.е. не является синтетическим.1. An analgesic agent based on plasmid DNA, with which the defensin NP-1 gene is expressed in mammalian cells, or the defensin NP-1.2 gene modified to increase intrinsic expression. The analgesic according to claim 1 for the introduction into the human body and mammals in order to relieve pain of any etiology. The analgesic according to claim 1, characterized in that it is obtained using methods of molecular biology, microbiology and recombinant DNA, i.e. not synthetic.

Claims (3)

1. Анальгетическое средство на основе плазмидной ДНК, с которой в клетках млекопитающих экспрессируется ген дефенсина NP-1, либо модифицированный для увеличения собственной экспрессии ген дефенсина NP-1.1. An analgesic agent based on plasmid DNA, with which the defensin NP-1 gene is expressed in mammalian cells, or the defensin NP-1 gene modified to increase intrinsic expression. 2. Анальгетическое средство по п.1 для введения в организм человека и млекопитающих с целью снятия болевого синдрома любой этиологии.2. The analgesic according to claim 1 for the introduction into the human body and mammals in order to relieve pain of any etiology. 3. Анальгетическое средство по п.1, характеризующееся тем, что получено с использованием методов молекулярной биологии, микробиологии и рекомбинантных ДНК, т.е. не является синтетическим. 3. The analgesic agent according to claim 1, characterized in that it is obtained using methods of molecular biology, microbiology and recombinant DNA, i.e. not synthetic.
RU2012114261/10A 2012-04-10 2012-04-10 ANALGETIC PRODUCT BASED ON PLASMID DNA RU2012114261A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
RU2012114261/10A RU2012114261A (en) 2012-04-10 2012-04-10 ANALGETIC PRODUCT BASED ON PLASMID DNA

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
RU2012114261/10A RU2012114261A (en) 2012-04-10 2012-04-10 ANALGETIC PRODUCT BASED ON PLASMID DNA

Publications (1)

Publication Number Publication Date
RU2012114261A true RU2012114261A (en) 2013-10-20

Family

ID=49356902

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2012114261/10A RU2012114261A (en) 2012-04-10 2012-04-10 ANALGETIC PRODUCT BASED ON PLASMID DNA

Country Status (1)

Country Link
RU (1) RU2012114261A (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2597789C2 (en) * 2014-11-10 2016-09-20 Илья Владимирович Духовлинов Analgetic agent on the basis of plasmid dna coding hnp-1, or hnp-2, or hnp-3 (versions)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2597789C2 (en) * 2014-11-10 2016-09-20 Илья Владимирович Духовлинов Analgetic agent on the basis of plasmid dna coding hnp-1, or hnp-2, or hnp-3 (versions)

Similar Documents

Publication Publication Date Title
BR112015024605A2 (en) systems and methods for targeted therapeutic protein production within target cells
CY1121217T1 (en) METHODS FOR HARVESTING MAMMAL CELL CULTURES
EA201400993A1 (en) ANTIBODIES AGAINST THE EPIDERMAL GROWTH FACTOR RECEPTOR, ACTIVE IN CERTAIN CONDITIONS AND METHODS OF THEIR APPLICATION
WO2016106404A3 (en) Methods and compositions for treating malignant tumors associated with kras mutation
EA201491470A1 (en) COMPOSITIONS OF FACTOR VIII AND METHODS OF OBTAINING AND USING SIMILAR
EA201792441A2 (en) FIBRONECTIN TYPE III DOMAINS CONNECTING WITH A PROSTATSPECIFIC MEMBRANE ANTIGEN
MX2018010529A (en) Compositions and methods for the improved production and delivery of rna by efficient transcription termination.
BR112015014752A2 (en) compounds and methods for kinase modulation, and indications for this
MX2013003681A (en) Engineered nucleic acids and methods of use thereof.
EA201490627A1 (en) COMPOUNDS FOR IMPROVED VIRAL TRANSDUCTION
BR112013023774A2 (en) glycosylceramide synthase inhibitors
MX2016005824A (en) Cell culture method.
AR092879A1 (en) G3P FUSION PROTEINS AS AGENTS OF UNION TO AMILOIDE
MX2018003757A (en) Compositions and methods for producing dendritic cells.
BR112014002173A2 (en) purified proteins
GB201013215D0 (en) Expression of antibody or a fragment thereof in lactobacillus
MY180183A (en) Methods and compositions for preventing norleucine misincorporation into proteins
EA202190727A3 (en) RECOMBINANT NUCLEIC ACID, VECTOR CONTAINING IT, AND METHOD FOR CELL TRANSFECTION
MX2018010196A (en) Targeted therapeutic lysosomal enzyme fusion proteins, associated formulations and uses thereof.
MX2019005693A (en) Red blood cell targeted factor viii and method of using the same.
RU2012114261A (en) ANALGETIC PRODUCT BASED ON PLASMID DNA
MX350005B (en) Pentose fermenting microorganisms.
EA201791442A1 (en) METHODS OF TREATMENT OF HEMATOLOGICAL DISTURBANCES, SOLID TUMORS OR INFECTIOUS DISEASES WITH THE USE OF NATURAL CELL-CALLERS
MX2017013206A (en) Optimized nucleotide sequence and pharmaceutical composition based thereon with prolonged vegf transgene expression.
EA201790642A1 (en) ALLEL-SPECIFIC THERAPY FOR HAPLOTYPES OF HANTINGTON'S DISEASE